CHINARES PHARMA (03320) intends to participate in the establishment of a fund.

CHINARES PHARMA (03320) announced that CHINARES PHARMA (Shantou), China Resources Double-Crane Pharmaceutical, Shuanghe (Beijing), and CHINARES PHARMA Investment (each a subsidiary of the company) are in negotiations with Hanweihuayu Shantou and other potential partners to establish a fund with an expected size of 500 million RMB. The fund is expected to mainly invest in high-growth enterprises in the fields of synthetic biology, innovative drugs, and biotechnology. The Group intends to commit an expected total investment amount of not more than 123 million RMB, accounting for approximately 24.6% of the fund's total committed investment amount. It is expected that Shenzhen China Resources Capital will be commissioned as the fund manager for the fund after its establishment.